Novartis milestones be proud ! Management take a bow !

Quote
Shit's getting ready to hit the fan , no surprise vasella bailed

Novartis Says U.S. Unit Subpoenaed .

By JEANNE WHALEN And PETER LOFTUS

Swiss drug giant Novartis AG NOVN.VX -0.64% said its U.S. unit has been subpoenaed as part of a federal investigation into the company's marketing of blood-pressure drug Tekturna and other products.

In its 2012 annual report, Novartis said the subpoena, received last year from the U.S. attorney's office for the Western District of Kentucky, requested marketing documents, including any relating to payments to health-care providers. The investigation is "civil and criminal in nature," Novartis said, adding that it is cooperating with the probe.

Novartis also disclosed in its annual report that U.S. authorities are investigating the export of products made by the company's Alcon eye-care unit to various countries subject to U.S. trade sanctions, including Iran.
 






Sandoz is one of the most poorly run facilities I've ever worked at. From the Site leadership to the upper management, they try to sweep everything under the rug. When the heat is on, they spend money fixing things and when the heat is off, slash the budgets. No wonder they are in the compliance trouble they are in. Someone needs to clean house
 












So...did this put patients first ???

Bloomberg News

J&J Gets EU Complaint With Novartis on Pay-for-Delay Deal
By Aoife White on January 31, 2013


Johnson & Johnson (JNJ) and Novartis AG (NOVN) were sent antitrust objections by European Union regulators over a pay-for-delay deal that may have hampered the sale of generic versions of pain killer fentanyl in the Netherlands.

The European Commission said the Dutch units of both companies struck a so-called co-promotion agreement in July 2005 to avoid rivaling each other. This deprived Dutch fentanyl customers of access to a cheaper pain killer for 17 months, it said in an e-mailed statement today.

“The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care,” EU Competition Commissioner Joaquin Almunia said in the statement.

Antitrust regulators on both sides of the Atlantic are focusing on how settlements between companies that make branded medicines and generics producers might harm consumers. Les Laboratoires Servier, H. Lundbeck A/S (LUN) and Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest generic drugmaker, were already sent so-called statements of objections in probes over possible delays for generic drugs.

Novartis “will closely examine the statement of objections and will avail themselves of their rights of defense,” said Eric Althoff, a spokesman for the Basel, Switzerland-based company. The EU complaint allows the company “the opportunity to comment on the factual and legal issues that led the commission to believe that an infringement of the EU competition rules may have occurred.”

Monthly Payments

Carol Goodrich, a spokeswoman for New Brunswick, New Jersey-based Johnson & Johnson, didn’t immediately respond to a call and an e-mail seeking comment.

Regulators said the deal foresaw monthly payments between J&J’s Janssen-Cilag unit and Novartis subsidiary Sandoz as long as Novartis avoided a generic version of the drug. This delayed Novartis’s sale of generic fentanyl patches until December 2006, the EU said.

Almunia said it was important to make sure that pharmaceutical companies don’t “free ride our welfare state and insurance systems” as EU governments face constraints on public spending, according to the press release.

An EU statement of objections lays out the antitrust agency’s case before it takes a final decision on whether the companies violated the law. While the EU can impose fines of as much as 10 percent of yearly sales, fines are usually based on sales of the product involved.
 






OTC plant bites Novartis' reputation again

Company recalls cough syrups after child hospitalized

February 1, 2013 | By Eric Palmer


The closed Novartis ($NVS) consumer products plant in Lincoln, NE, that has besmirched the drug giant's reputation and frustrated CEO Joseph Jimenez has bitten the company again.

This time Novartis acknowledged that its poor manufacturing resulted in four children popping off "childproof" caps on cough syrups and taking a drink. Spokeswoman Julie Masow told FiercePharma that one of the children was hospitalized but fully recovered.

More than a year after Novartis closed the plant to address the substantial shortcomings FDA inspectors found there, it is recalling 183 lots of cough and cold products during the worst flu season in the U.S. in several years. Masow said that because the products were manufactured before December 2011, about 97% is believed to have been used or returned. "It is unlikely much of it remains on shelves or in consumers' homes," Masow said. The products themselves are safe and the recall is "voluntary and precautionary," she said.

The plant problems have plagued the company since FDA inspectors found pages of shortcomings during inspections and Novartis voluntarily closed it in December 2011. The expense of fixes and the lost revenue from limited lines of over-the-counter (OTC) products for sale has been a drag on Novartis' earnings. In the third quarter, OTC sales were off 22% to $938 million. Delays required Jimenez to eat his words about when the plant would reopen and finally just say he no longer would make predictions. Questions raised by the plant problems and others in the Swiss company's manufacturing also led him to launch a program for employees to focus on quality.

The company had actually started ramping up production of some products, like Excedrin Migraine, in the fall and returning them to retailers. A consumer complaint about the cough products in late November triggered an internal investigation, which led Novartis Consumer Health to bite the bullet and recall whatever of the products might still be unused.
 






Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect

– Voluntary recall of certain lots of Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids, issued to consumers, retail customers and wholesalers in Curacao

– Consumers who may have the product(s) being recalled are asked to return the affected products and receive a full refund

– The products being recalled were produced at a Novartis Consumer Health manufacturing facility in the United States prior to the voluntary suspension of operations in December 2011, and at a third-party manufacturing site in Canada using the same bottle and cap components


PANAMA CITY, Feb. 5, 2013 /PRNewswire/ – Novartis Pharma Logistics, Inc. announced today that it is voluntarily recalling certain lots of Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids. Novartis Pharma Logistics has decided to issue a voluntary recall to consumers, retail customers and wholesalers in Curacao because the child-resistant feature of the bottle cap may not function properly, enabling the cap to be removed with the tamper-evident seal still in place. The affected bottle sizes are included at the end of this release.

In the United States Novartis received four adverse events for Triaminic® Syrups related to this issue.

Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids continue to be safe and effective when used as directed on the package label.

The products being recalled were produced at a Novartis Consumer Health manufacturing facility in US prior to the voluntary suspension of operations in December 2011. In addition to production at the US manufacturing site, Buckley’s Complete® was also produced until January 2013 at a third-party manufacturing site in Canada. A consumer complaint in the US in late November 2012 triggered an internal investigation by Novartis Consumer Health that determined a voluntary recall was in the best interest of consumers.

Action to be taken by consumers
Novartis Pharma Logistics advises consumers who believe they have product included in this recall to discontinue use and return the recalled product to the store or pharmacy where it was purchased for a full refund. Only recalled product in the original bottle will be eligible for a refund. Consumers may contact the Novartis Consumer Relationship Center at 877-769-8420 (available Monday-Saturday 8 a.m. to 6 p.m. Eastern Time) for more detailed information about the recall, including which products are impacted, and for information on how to return the affected products and receive a full refund.

Action to be taken by retailers and wholesalers
Retailers and wholesalers should stop distribution and return the affected lots using the Novartis Product Return information that is being provided to them. Retailers that receive product returns from consumers will be reimbursed by Novartis Pharma Logistics.

This recall is being conducted with the full knowledge of the Curacao Public Health Department.
 






BUYER BEWARE !! THERE'S A REASON VASELLA BAILED !!!!!!

Moody’s Cuts Novartis to Aa3 as Buybacks Slow Alcon Debt Payment

By Eva von Schaper - Feb 8, 2013 6:51 AM ET.

Novartis AG’s long-term credit rating was cut one grade by Moody’s Investors Service to Aa3 because the company is slow to pay down debt from its 2010 acquisition of a majority stake in Alcon Inc.

By the end of 2012, Novartis had not paid down enough of its debt to merit an Aa2 rating, Moody’s said. Novartis probably won’t be able to raise its rating in 2013 because it faces patent expiries, costs linked to manufacturing setbacks at its Lincoln, Nebraska, site and unusually high investments in plants and equipment.

A Novartis spokesman didn’t immediately reply to a request for comment.
 






UK cost agency says 'no' to Novartis blood cancer drug Jakavi

LONDON Feb 13 (Reuters) - A new drug from Novartis for myelofibrosis, a rare blood cancer, is not worth using on the state health service, Britain's healthcare cost watchdog said on Wednesday.

The National Institute for Health and Clinical Excellence (NICE) said it had issued new draft guidance not recommending Jakavi because it could not be considered a cost-effective use of resources.

The drug costs 3,600 pounds ($5,600) for a 60-tablet pack, corresponding to an annual cost of approximately 43,200 pounds per patient.

Jakavi, which was licensed from Incyte, was given a marketing authorisation in Europe last August.
 






WOW ! WOW !! WOW !!! but NVS can only afford a 1% raise for you ( if you're lucky) so when's the revolution coming ?? These are ALWAYS friday afternoon stories LMFAO !!

Vasella to get up to 72 mln Sfr after leaving Novartis

Fri Feb 15, 2013 2:37pm EST

ZURICH Feb 15 (Reuters) - Novartis Chairman Daniel Vasella said he will receive up to 72 million Swiss francs ($77.94 million) over the next six years after leaving the company this month, news that might play into the hands of supporters of a referendum to limit "fat cat" pay.

Vasella told Swiss TV SRF on Friday he will be entitled to annual payments of 12 million francs if he respects the clauses of his contract banning him from working for a competitor.

"So that would add up to 72 million francs within six years," he told TV news magazine "Tagesschau.

The news comes two weeks ahead of a referendum on March 3 in which Swiss voters will decide whether they want to give shareholders in Swiss companies a veto over executive pay deals.

Politicians questioned by Swiss TV said they were shocked about the high amount Vasella would receive after leaving the Basel-based pharma company, with minister Simonetta Sommaruga saying she was "speechless."

Polls show 65 percent would approve the initiative - the brainchild of businessman Thomas Minder - who has tapped public ire over lavish bonuses blamed for fuelling a high-risk culture that nearly felled Swiss bank UBS.
 






http://www.bloomberg.com/news/2013-...novartis-payout-boosts-fat-cat-crackdown.html

or

Monday, 18 February, 2013, 06:50
Outrage over Novartis chairman's severance


By Jo Fahy, World Radio Switzerland


Outgoing Novartis chairman, Daniel Vasella, is to receive a 72-million Swiss franc severance package, a sum that is causing outrage across the country

The drug company’s board agreed to the deal, which includes a clause against Vasella working for the competition.

It’ll be paid to him over the course of six years.

Despite pledging to donate the proceeds to charity, Vasella’s payoff has been widely criticised.

Shareholders advocate and former federal administrative judge, Hans-Jacob Heitz, said he intended to start a lawsuit against Vasella and the Novartis board on Monday, for abusing shareholders’ rights.

Justice minister Simonetta Sommaruga meanwhile told Swiss Public Television she was “speechless.” Federal Councillor Johann Schneider-Ammann added, it was an “ugly affair.”

The payout has been widely perceived as fuel for the upcoming Minder initiative.

The public will vote on March 3 to give shareholders veto-powers over large bonus packages and compensation for top executives and managers.

or


$78 million golden parachute for Novartis' Daniel Vasella


POSTED: Monday, February 18, 2013, 7:08 AM

Novartis will pay Chairman Daniel Vasella $78 million when he departs the Swiss drugmaker, the Wall Street Journal reported over the weekend.

Vasella will get his money - as long as he doesn't work for some other pharmaceutical company for six years.

Many people will shake their heads at the idea of getting more for not working.

Getting that deal in health care is more problematic for some because human health is viewed differently than making widgets or steel or TV sets.

But the high-price of the golden parachute is so high that, according to the Journal, even stockholders and groups representing investors hope to use it to argue for tighter rules on executive compensation in a very business-friendly country.

The Journal reported that Vasella said in an email to the paper that he would donate the proceeds to philanthropic and charitable organizations.

"It has been very important to Novartis that I refrain from making my knowledge and know-how available to competitors and to take advantage of my experience with the company," Vasella said in the statement. "In return, the Novartis Board of Directors agreed to make annual payments according to fair market value provided I fulfill all my obligations."
 






HAW HAW :) FUCK YOU DAN !!! XD !!!!

Novartis shareholder revolt costs boss his $78m 'golden gag'

Swiss pharmaceuticals group cancels non-compete agreement with outgoing chairman Daniel Vasella after furious reaction

The Guardian, Tuesday 19 February 2013 14.24 EST


Daniel Vasella had offered to give away some of the payment he was to receive to prevent him from giving advice to competitors after he steps down from the Novartis board.


Shareholder activism over corporate pay has claimed one of its biggest victories yet after the Swiss pharmaceutical group Novartis was forced to abandon the award of a $78m "golden gag" non-compete payment to its outgoing chairman.

The UK investor advisory body, Pirc, said the move could inspire a repeat of last year's "shareholder spring" when a series of rebellions over pay forced out the chief executives of Aviva, AstraZeneca and Trinity Mirror.

Shareholders in Novartis reacted with fury over the weekend when it emerged that Daniel Vasella was to receive the payment – $13m a year over six years – to prevent him from giving advice to competitors after he steps down from the board this week. Vasella's attempt to deflect their anger by pledging to give some of the money away to philanthropic causes was unsuccessful, as investor anger became amplified by criticism from the Swiss public. On Tuesday, the company said the board of directors and Vasella had agreed to cancel the non-compete agreement in the light of the furious response.

"I have understood that many people in Switzerland find the amount of the compensation linked to the non-compete agreement unreasonably high, despite the fact I had announced my intention to make the net amount available for philanthropic activities. That is why I have recommended to the board that I forgo all payments linked to the non-compete agreement," Vasella said in a statement.

A spokesman for Pirc said the turnaround marked an important victory for shareholders in the UK. Pirc has recommended to its clients that they vote against every long-term bonus plan published this year. "Both the scale and the nature of the payment were clearly going to inflame investor and public opinion. Although the board has ultimately reached the right decision, this situation should never have arisen in the first place. As we gear up for the UK season, hopefully this victory will give shareholders here greater confidence that they, too, can successfully challenge inappropriate remuneration arrangements," the spokesman said.

The Novartis reversal comes as Switzerland prepares for its own equivalent of a shareholder spring, with a national referendum on 3 March to decide whether shareholders should wield a veto over excessive executive pay.

The backlash began among shareholders, the public and the business community last week when news of it emerged on a Swiss blog. On Monday, a criminal complaint was filed on behalf of shareholders against Vasella and the company's compensation committee for breach of trust and untruthful business information.

Roby Tschopp, head of shareholder group Actares, described the payment as an outrage.

In a statement on Tuesday, Novartis vice-chairman Ulrich Lehner said: "We continue to believe in the value of a non-compete; however, we believe the decision to cancel the agreement and all related compensation addresses the concerns of shareholders and other stakeholders. The board understands the importance of full transparency and will strengthen its efforts in this regard."

In the UK, Pirc's support was echoed by the Institute of Directors (IoD), which represents 37,000 company directors. It said the payment to Vasella had been difficult to justify and called on companies to pay attention to their shareholders.

"Such an exceptional payment could only be viewed as legitimate if it had the explicit support of shareholders – it evidently did not, and it is a good sign that they stood up and pressed their concerns home," said Roger Barker, head of corporate governance at the IoD. "Efforts to strengthen the role of shareholders in issues of executive pay in Switzerland are to be welcomed. Shareholder engagement with companies over key areas of governance, such as executive pay, is an important component of modern corporate governance and should be embraced by companies and boards."

Recent polls indicate that some 65% of voters in Switzerland are in favour of measures proposed in the forthcoming referendum which will ban "golden handshakes" for new staff and "golden parachutes" for those departing. If the proposals are successful, there will also be restrictions on the terms of board members to one year.

The main backer of the changes is Thomas Minder, a businessman who has campaigned against large-scale bonuses in Switzerland.


A growing backlash


The defeat of Daniel Vasella's $78m (£50.6m) non-compete agreement is the latest corporate pay reversal due to pressure from the public, shareholders and politicians. Here is a selection of other notable rebellions over executive pay.
 






YOU HAD TO SEE THIS BACK CHANNEL EMBEZZLEMENT COMING FROM DAN VASELLA & THE NOVARTIS BOARD OF DIRECTOR SCUM , DAN HAS ALREADY FLEECED OVER $300 MILLION IN 17 YEARS & YET THIS BLOODSUCKER WANTS MORE MORE MORE

Novartis Is Negotiating Consulting Agreement With Vasella

By Simeon Bennett & Patrick Winters - Feb 22, 2013 6:20 AM ET.

Novartis AG (NOVN) is negotiating a consulting agreement with Chairman Daniel Vasella, the company’s top lawyer said, three days after the drugmaker scrapped an accord to pay Vasella as much as $78 million for not competing with Novartis after he steps down today.

The outcome of the consulting talks will be communicated publicly, General Counsel Felix Ehrat said at the company’s annual shareholder meeting today in Basel, Switzerland. Vasella, 59, won’t be paid for his role as honorary chairman, but will have an office, administrative support and security, Ehrat said.

Shareholders grilled Vice Chairman Ulrich Lehner and Novartis executives today about the non-compete agreement, which caused an uproar in Switzerland last week, two weeks before voters cast ballots in a March 3 referendum to limit executive pay. The company announced that the agreement existed, without disclosing financial details. The blog Inside ParadePlatz revealed the amounts involved on Feb. 15, and the company subsequently confirmed it.

Without the leak, “then no one would have known about the gigantic sums you were talking about,” Dominique Biedermann, executive director of Ethos, a foundation that advises institutional investors on corporate governance issues, said at todays meeting. “That leaves a very bad impression of how the board of directors works here. We had the impression none of you have the courage to stand up to” Vasella.
 






AGAIN !

Novartis Sues To Block Generic Reclast, Zometa Drugs

By Linda Chiem
Law360, New York (February 22, 2013, 1:58 PM ET) -- Novartis Pharmaceuticals Corp. filed a lawsuit Wednesday in New Jersey federal court seeking to bar more than a dozen drugmakers from making generic versions of its osteoporosis drug Reclast and oncology drug Zometa.

Novartis is seeking to prevent drugmakers such as Actavis LLC, Apotex Inc., Sun Pharmaceuticals Industries Inc., Wockhardt USA LLC and others from producing zoledronic acid, the active ingredient in Reclast and Zometa, which they purportedly intend to launch on or soon after March 2 — the day the exclusivity on Novartis' three patents...
 






Law360, New York (March 04, 2013, 8:00 PM ET) -- A Florida jury slapped Novartis Pharmaceuticals Corp. with a $250,000 verdict on Wednesday in multidistrict litigation over injuries allegedly caused by the bone drug Zometa, though it declined to impose punitive damages on the drugmaker.

The plaintiff, Florida resident J. Hunter Chiles, claimed that Novartis failed to warn that Zometa, a bisphosphonate he took to treat his multiple myeloma, could cause the bone disease osteonecrosis of the jaw. The suit is part of the multidistrict litigation targeting Zometa and an older Novartis bone drug, Aredia
 






Actavis (ACT) Confirms Generic Version Of Novartis' (NVS) Dementia Therapy

March 08, 2013 10:20 AM

(By Balaseshan) Actavis Inc. (NYSE: ACT : 87.56, 0.9), a specialty pharmaceutical company, said it has confirmed the generic version of Novartis AG's (NYSE: NVS : 68.68, -0.09) Exelon Patch therapy to treat dementia associated with Alzheimer's or Parkinson's disease.

Actavis, formerly Watson Pharmaceuticals Inc., has confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength.

Actavis' ANDA product is a generic version of Novartis' Exelon Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Parkinson's disease.
 






Swiss Prosecutor Probing Novartis Board Members on Payout

By Eva von Schaper - Mar 12, 2013 6:58 AM ET.

A Swiss prosecutor is probing Novartis AG (NOVN)’s former Chairman Daniel Vasella and other board members after two criminal complaints related to Vasella’s 72 million-Swiss franc ($75 million) payout were filed in Basel.

The public prosecutor is investigating whether Novartis executives can be charged, Peter Gill, the prosecutor’s spokesman, said in a telephone interview today.

Vasella’s “golden parachute” came to light after details were leaked to the press, leading to a public outcry in Switzerland and prompting Vasella to give up the money. Vasella and the board’s compensation committee failed to disclose the payments to shareholders, said Hans-Jacob Heitz, a lawyer who filed one of the complaints charging the executives with breach of trust and providing untruthful business information.

“They should have disclosed the payment in the last annual report at the latest,” Heitz said in a telephone interview today. Heitz didn’t say how many shareholders he represents. The other complaint was filed anonymously, according to Gill.

Ulrich Lehner, who may be named head of ThyssenKrupp AG (TKA)’s supervisory board, was a member of key Novartis board committees involved in the payout, Heitz said.

The probe, an “absolutely” normal procedure, may take another couple of weeks, Gill said.

Spokesmen for Novartis and ThyssenKrupp weren’t immediately available for comment.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net
 






Italian antitrust agency probes alleged Roche-Novartis cartel

Eye docs, clinics want to use Avastin, but Lucentis is the only approved option

February 20, 2013 | By Tracy Staton

Italian antitrust watchdogs have entered the Avastin-vs.-Lucentis fray. The Italian Competition Authority opened an investigation of Roche and Novartis on suspicion of a "cartel" designed to preference the vision-loss drug Lucentis over Avastin, the cancer drug sometimes used off-label in eye treatments.

Italian Ophthalmological Society and an association of private healthcare facilities each filed a complaint alleging that Roche and Novartis might have an "illicit agreement" to keep Avastin out of the eye business. The filings claim that the alleged cartel costs hundreds of millions of euros per year. Roche developed Lucentis, and Novartis markets it in Europe.

Eye doctors often use Avastin off-label in patients with macular degeneration and other vision-robbing disorders. It's a far cheaper option than Lucentis, which was developed specifically for injection into the eye. And some researchers have found that the treatments are roughly equal, efficacy-wise, in patients with wet age-related macular degeneration.

Cost-conscious customers keep turning to Avastin--or trying to. The Italian probe is just the latest scrap over ophthalmic use of the drug. Some eye doctors in the U.S. raised a ruckus several years ago, claiming that Roche's Genentech unit had clamped down on distribution to keep Avastin out of their hands. More recently, Novartis prevailed in a fight over Avastin use by some doctors on the U.K.'s National Health Service; after offering a discount on Lucentis, the NHS doctors agreed to abandon off-label Avastin.

The competition agency visited the Italian offices of Roche and Novartis, looking for evidence, on Valentine's Day, the agency said in a statement. It plans to wrap up its probe by Dec. 20.
 






UK Court Revokes 2 Novartis Patents In Bone Drug Row

Law360, Los Angeles (March 15, 2013, 8:18 PM ET) -- A U.K. court on Friday revoked two European patents for zoledronate, agreeing with generic-drug makers Hospira UK Ltd. and Mylan Inc. that Novartis AG wasn't the first to discover its effectiveness as an osteoporosis treatment.

The U.K. High Court of Justice sided with Hospira and Mylan over the idea that treating osteoporosis with zoledronic acid, also known as zoledronate, was common in the scientific community when Novartis filed its European patents for zoledronate in June 2000.
 






Patents REVOKED said:
UK Court Revokes 2 Novartis Patents In Bone Drug Row

Law360, Los Angeles (March 15, 2013, 8:18 PM ET) -- A U.K. court on Friday revoked two European patents for zoledronate, agreeing with generic-drug makers Hospira UK Ltd. and Mylan Inc. that Novartis AG wasn't the first to discover its effectiveness as an osteoporosis treatment.

The U.K. High Court of Justice sided with Hospira and Mylan over the idea that treating osteoporosis with zoledronic acid, also known as zoledronate, was common in the scientific community when Novartis filed its European patents for zoledronate in June 2000.
Click to expand...

Now we can add: stealing other people's patent to number of misconducts ( illegal shit) this company has done and will do till someone stops them.After we heard the latests about Vasella and investigation of his 'irregularities", nothing surprises. His biggest legacy is the introduction of use of criminal/illegal practices in big way as part of Novartis' modus operandi.
But now it seems the house of cards is about to fall down. No wonder he got the hell out or more likely got fired by board of directors even though they are crooked too, but not that crooked.
The rats will be leaving the Novartanic. What will happen to all of you loyal implementors of policies, plans and orders?
 






UK cost body rejects Novartis breast cancer drug
3/20/2013

LONDON (Reuters) - Novartis drug Afinitor, expected to be a big seller for the Swiss group, has been rejected by Britain's health cost agency NICE due to uncertainty over its survival benefits in breast cancer.

Novartis said it was "extremely disappointed" by Thursday's draft decision from the National Institute for Health and Clinical Excellence.

"Using the most appropriate estimates, the committee concluded that everolimus is not a cost-effective treatment option for the NHS (National Health Service)."
 






Top Bottom
Back
Quote